1 Kenter MJH, Cohen AF. Establishing risk of human experimentation with drugs: lessons
from TGN1412. Lancet 2006; 368: 1387–91. 2 TeGenero Immunotherapeutics Investigator's …

In their Viewpoint (Oct 14, p 1387), 1 Marcel Kenter and Adam Cohen criticise the
assessment of preclinical safety and mode-of-action data for TGN1412—an anti-CD28 …

Administration of a chemical or biological compound to a human being is never without risk.
Although knowledge about risks increases during the development process, risks are still …

The severe side-effects seen in the clinical trial of TGN14121, 2 were not seen in preclinical
tests on non-human primates. 3 Apart from differences in affinity and percentages of memory …

In their scientific analysis of the disastrous TGN1412 trial, MJH Kenter and AF Cohen (Oct
14, p 1390) 1 conclude that “the antibody was a high-risk compound unlikely to be suitable …

In their scientific analysis of the disastrous TGN1412 trial, MJH Kenter and AF Cohen (Oct
14, p 1390) 1 conclude that “the antibody was a high-risk compound unlikely to be suitable …

In their scientific analysis of the disastrous TGN1412 trial, MJH Kenter and AF Cohen (Oct
14, p 1390) 1 conclude that “the antibody was a high-risk compound unlikely to be suitable …

The Article by Charles Knowles and colleagues (Oct 24, p 1640) 1 reports outcomes that are
different from those initially registered. 2 The Article reports the single prespecified primary …

2 UN Economic and Social Council. Annexes to the list of issues in relation to the sixth
periodic report of Germany. Replies of Germany to the list of issues. New York, NY: United …

Comment www. thelancet. com Vol 369 May 5, 2007 1497 infusions would clearly have
been beneficial. The regimen was explained to volunteers as:“For practical reasons, the time …